China’s Xi speaks with Trump by phone, discusses Taiwan and bilateral ties
Chad M. Robins, CEO and Chairman of Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 89,265 shares of common stock between November 10 and November 12, 2025, for approximately $1.3 million.
According to a Form 4 filing with the Securities and Exchange Commission, the sales were executed in three separate transactions. On November 10, Robins sold 86,161 shares at a weighted average price of $14.73, for a total value of $1269259. These shares were sold in multiple transactions at prices ranging from $14.37 to $15.05. On November 11, he sold 1,237 shares at a weighted average price of $14.57, with prices ranging from $14.52 to $14.66, for a total value of $18028. On November 12, Robins sold 1,867 shares at a weighted average price of $15.00, with prices ranging from $15.00 to $15.03, for a total value of $27998.
The transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on August 11, 2025. Following these transactions, Robins directly owns 2,869,975 shares of Adaptive Biotechnologies Corp.
In other recent news, Adaptive Biotechnologies reported impressive financial results for the third quarter of 2025. The company exceeded market expectations with an earnings per share (EPS) of $0.06, significantly higher than the forecasted -$0.17. This represented a surprise of 135.29%. Additionally, Adaptive Biotechnologies’ revenue reached $94 million, surpassing the anticipated $60.48 million by 55.37%. These results highlight the company’s strong performance in the recent quarter. Analysts had projected lower figures, making these results noteworthy. The positive earnings and revenue figures are crucial information for investors evaluating the company’s financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.